This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The study was sponsored by Baxalta, a member of the Takeda group of companies.
Hu X, et al. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review : 29 Dec 2019. Available from: URL: https://doi.org/10.1186/s13561-019-0257-3
About this article
Cite this article
Pegaspargase preferred option in acute lymphoblastic leukaemia. PharmacoEcon Outcomes News 844, 30 (2020). https://doi.org/10.1007/s40274-020-6493-2